Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Outlook Therapeutics (OTLK) Equity Average (2016 - 2025)

Historic Equity Average for Outlook Therapeutics (OTLK) over the last 7 years, with Q4 2025 value amounting to -$35.4 million.

  • Outlook Therapeutics' Equity Average fell 7987.83% to -$35.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$35.4 million, marking a year-over-year decrease of 7987.83%. This contributed to the annual value of -$20.8 million for FY2019, which is 2959.94% up from last year.
  • Latest data reveals that Outlook Therapeutics reported Equity Average of -$35.4 million as of Q4 2025, which was down 7987.83% from -$34.7 million recorded in Q3 2025.
  • In the past 5 years, Outlook Therapeutics' Equity Average registered a high of -$19.7 million during Q4 2024, and its lowest value of -$41.4 million during Q1 2025.